Sign in
CompletedNo phase

Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study

Key facts

Who runs it
Nanjing First Hospital, Nanjing Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
400 people enrolled
Started
31 Mar 2024
Ended
10 Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tegoprazan-amoxicillin dual therapy
Record updated
5 March 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age 18-65 years old
  • Patients who have had a positive 13C or 14C breath test and have not received Helicobacter pylori eradication therapy before, or who have failed to eradicate in the early stage but have not received eradication therapy within half a year
  • Voluntarily join this trial and sign the informed consent form

Who cannot take part

  • Patients who have received Helicobacter pylori eradication therapy within half a year
  • Use of antibiotics, bismuth, histamine H2 receptor antagonists or PPIs for 4 weeks before starting study treatment
  • use of adrenocorticosteroids, non-steroidal anti-inflammatory drugs or anticoagulants
  • Suffering from serious concomitant diseases, such as liver disease, cardiovascular disease, lung disease, kidney disease
  • Allergy to the study drug (penicillin, amoxicillin, furazolidone, Tegoprazan, etc.)
  • Patients with active peptic ulcer disease
  • History of esophageal or gastric surgery
  • Gastric mucosa-associated lymphoid tissue lymphoma (MALT), malignant tumor diseases
  • Pregnant or lactating women
  • Alcoholism

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To compare the efficacy and safety of Tegoprazan-amoxicillin dual therapy and bismuth quadruple therapy based on furazolidone in the treatment of Helicobacter pylori eradication, the eradication rate, patient compliance, and adverse drug reactions of H. pylori infection were compared in a multi-center clinical joint study in Jiangsu Province.

The 2 groups in the trial

  • Group ATreatment being tested

    oral Tegoprazan 50 mg, bid+amoxicillin 1000 mg, tid. The duration of treatment is 14 days.

    Treatment: Tegoprazan-amoxicillin dual therapy

  • Group BExisting treatment, for comparison

    oral Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid. The duration of treatment is 14 days.

    Treatment: Tegoprazan-amoxicillin dual therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
5 March 2026